Related Experiment Video

Updated: May 28, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Molecular pathology of gastric cancer: research and practice

Wataru Yasui1, Kazuhiro Sentani, Naoya Sakamoto

  • 1Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Minami-ku, Hiroshima, Japan. wyasui@hiroshima-u.ac.jp

Pathology, Research and Practice
|October 19, 2011
PubMed

Insights

Molecular stomach carcinogenesis involves pathways like CDX2-Reg IV-SOX9 for intestinal phenotypes and markers OLFM4/CLDN18 for gastric phenotypes. Epigenetic changes via microRNAs and genetic polymorphisms also drive gastric cancer risk and progression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gastroenterology

Background:

  • Gastric cancer development is a complex process involving multiple molecular events.
  • Understanding these molecular alterations is crucial for improving diagnosis and treatment.
  • Recent research highlights key pathways, epigenetic factors, and cellular components involved.

Purpose of the Study:

  • To review recent advances in the molecular understanding of stomach carcinogenesis.
  • To identify key molecular markers and pathways associated with different gastric cancer phenotypes.
  • To discuss the role of microRNAs, genetic polymorphisms, and cancer stem cells in gastric cancer.

Main Methods:

  • Review of current scientific literature on molecular stomach carcinogenesis.
  • Analysis of molecular events associated with specific mucin phenotypes.
  • Examination of the role of microRNAs, genetic polymorphisms, and cancer stem cell markers.

Main Results:

  • The CDX2-Reg IV-SOX9 pathway is linked to the intestinal mucin phenotype of gastric cancer.
  • OLFM4 and CLDN18 are identified as novel markers for the gastric phenotype.
  • MicroRNAs (e.g., reduced miR-200) and PSCA polymorphism influence gastric cancer development and susceptibility.
  • Cancer stem cells, marked by CD44, exhibit self-renewal and chemoresistance, contributing to tumor heterogeneity.

Conclusions:

  • Molecular events, including specific pathways, microRNAs, and genetic variations, are critical in gastric carcinogenesis.
  • Distinct molecular markers differentiate gastric cancer phenotypes.
  • Cancer stem cells represent a significant factor in gastric cancer, though their origin requires further investigation.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...